Resmed inc. receives Investment Bank Analyst Rating Update
- Investing.com
Pro
- English (USA)
- English (UK)
- English (India)
- English (Canada)
- English (South Africa)
- English (Philippines)
- English (Nigeria)
- Deutsch
- Español (España)
- Español (México)
- Français
- Italiano
- Nederlands
- Polski
- Português (Portugal)
- Português (Brasil)
- Русский
- Türkçe
- العربية
- Ελληνικά
- Svenska
- Suomi
- עברית
- 日本語
- 한국어
- 简体中文
- 繁體中文
- Bahasa Indonesia
- Bahasa Melayu
- ไทย
- Tiếng Việt
- हिंदी
ResMed Inc (RMD)
Track the ResMed share price today and view real-time RMD share price data, including charts, technicals, and key financials. View the RMD premarket stock price ahead of the market session or assess the after hours quote. Explore RMD stock price movements, trading volume, and market activity across the NYSE exchange.
What Is the ResMed Stock Price Today?
The ResMed stock price today is 235.30.
What Is the Stock Symbol for ResMed?
The stock symbol for ResMed is ""RMD.""
What Stock Exchange Does ResMed Trade On?
ResMed is listed and trades on the NYSE stock exchange.
Is ResMed a Good Stock to Buy?
Determining whether ResMed or any stock is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the RMD quote. (ISIN: US7611521078)
What Is the ResMed Stock Price Today?
The ResMed stock price today is 235.30.
What Is the Stock Symbol for ResMed?
The stock symbol for ResMed is ""RMD.""
What Stock Exchange Does ResMed Trade On?
ResMed is listed and trades on the NYSE stock exchange.
Is ResMed a Good Stock to Buy?
Determining whether ResMed or any stock is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the RMD quote. (ISIN: US7611521078)
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
231.95
236.67
52 wk Range
180.27
277.67
RMD is not included in our AI-picked strategies. See which stocks are.
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
231.95236.67
52 wk Range
180.27277.67
Key Statistics
Edit
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
RMD Scorecard
Company’s Health
Assesses a company's financial position by analysing its market value, financial ratios, industry benchmarks, and competitors.
UnlockFair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Unlock PriceTechnical Analysis
Neutral
Price Target
264.33
Upside
+12.34%
Members' Sentiments
Bearish
Bullish
ProTips
Tips that distill complex financial data into concise, actionable investment insights.
High shareholder yield
ResMed Inc receives Investment Bank Analyst Rating Update- Investing.com
Pro
ResMed Inc receives Investment Bank Analyst Rating Update- Investing.com
Pro
ResMed Inc receives Investment Bank Analyst Rating Update- Investing.com
Pro
- Resmed inc. receives Investment Bank Analyst Rating Update
- Investing.com
Pro - ResMed Inc receives Investment Bank Analyst Rating Update
- Investing.com
Pro - ResMed Inc receives Investment Bank Analyst Rating Update
- Investing.com
Pro - ResMed Inc receives Investment Bank Analyst Rating Update
- Investing.com
Pro - ResMed Inc receives Investment Bank Analyst Rating Update
- Investing.com
Pro
Technical Analysis
Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Sell
Technical Indicators
Strong Sell
Moving Averages
Sell
Analyst Ratings
9 Buy
10 Hold
1 Sell
Ratings:
20 analysts
Overall Consensus
Buy
Analysts 12-Month Price Target:
Average 264.33
(+12.34% Upside)
ResMed Inc SWOT Analysis
Sleep Tech Dominance | ResMed's strong market position in sleep and respiratory care, driven by innovative products like AirSense 11, faces potential disruption from emerging GLP-1 drugs |
Financial Resilience | Explore ResMed's impressive financial performance, with double-digit revenue growth and improved operating margins, despite challenges in gross margins |
Market Expansion | Delve into ResMed's strategic moves beyond sleep apnea, targeting insomnia and COPD markets to diversify revenue streams and offset potential market share losses |
Analyst Perspectives | Price targets range from $180 to $280, reflecting varied views on ResMed's ability to navigate challenges from GLP-1 drugs and increased competition |
ResMed Inc Earnings Call Summary for Q1/2027
- ResMed Q1 earnings beat estimates with adjusted EPS of $2.91 vs. $2.68 expected; revenue reached $1.4B, up 6% YoY with gross margin expanding 50bps to 62.5%.
- Company repurchased $936M in stock during quarter, returning over $1B to shareholders including dividends; shares rose 2% in combined regular and after-hours trading.
- Management maintained full-year fiscal 2027 guidance of $5.75B-$5.85B revenue and $12.00-$12.25 EPS despite strong Q1, citing Q2 margin pressure from facility expansion costs.
- Life support device revenue declined sharply due to Astral field safety action with $42M reserve; company expects marketing campaigns to drive results in second half of year.
- Long-term outlook targets high single-digit annual revenue growth through 2030 with earnings growth outpacing sales; CFO emphasized sustainable growth over short-term gains.
Last Updated: 30/10/2026, 08:46 am
Read Full TranscriptEarnings
Latest Release
29/10/2026
EPS / Forecast
2.91 / 2.68
Revenue / Forecast
1.4B / 1.39B
Compare RMD to Peers and Sector
Metrics to compare | RMD | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipRMDPeersSector | |
|---|---|---|---|---|
P/E Ratio | 20.8x | 20.4x | −0.2x | |
PEG Ratio | 1.66 | 0.61 | 0.00 | |
Price/Book | 5.6x | 2.2x | 2.6x | |
Price / LTM Sales | 5.8x | 2.1x | 2.8x | |
Upside (Analyst Target) | 12.3% | 8.8% | 65.6% | |
Fair Value Upside | Unlock | 20.5% | 10.0% | Unlock |
ResMed Inc. engages in the digital health and cloud-connected medical devices business in the United States and internationally. It operates in two segments, Sleep and Breathing Health, and Residential Care Software. The company offers sleep recorders for the diagnosis and titration of sleep apnea in sleep clinics, hospitals, and at home, including ApneaLink Air, a portable diagnostic device that measures oximetry, respiratory effort, pulse, nasal flow, and snoring; NightOwl, a portable, cloud-connected, and disposable diagnostic device that measures AHI based on derived peripheral arterial tone, actigraphy, and oximetry; and EasyCare Tx, a sleep lab solution. It also provides AirView, a cloud-based system that enables remote monitoring and changing of patients’ device settings; myAir, a personalized therapy management application for patients with sleep apnea that provides support, education, and troubleshooting tools for increased patient engagement and improved compliance; and connectivity module which provides a cellular connection between compatible ventilation devices and AirView system. In addition, the company offers Brightree solutions which are solutions and services for organizations in home medical equipment and pharmacy, orthotic and prosthetic, and home infusion; HEALTHCAREfirst solutions that offers electronic health record, software, billing and coding services, and advanced analytics that enables home health and hospice agencies to optimize clinical, financial and administrative processes; MatrixCare EHR software as a service solutions used by skilled nursing and senior living providers, life plan communities, and home health and hospice sectors; and MEDIFOX DAN software solutions that is used by residential care providers, such as home health and nursing home providers. ResMed Inc. was founded in 1989 and is headquartered in San Diego, California.
Ownership
Ownership Overview
Top Holders
People Also Watch
FAQ
What Is the ResMed (RMD) Stock Price Today?
The ResMed stock price today is 235.30 USD.
What Stock Exchange Does ResMed Trade On?
ResMed is listed and trades on the New York Stock Exchange.
What Is the Stock Symbol for ResMed?
The stock symbol for ResMed is "RMD."
Does ResMed Pay Dividends? What’s The Current Dividend Yield?
The ResMed dividend yield is 1.1%%.
What Is the ResMed Market Cap?
As of today, ResMed market cap is 33.66B USD.
What Is ResMed's Earnings Per Share (TTM)?
The ResMed EPS (TTM) is 11.01.
When Is the Next ResMed Earnings Date?
ResMed will release its next earnings report on 28/01/2027.
From a Technical Analysis Perspective, Is RMD a Buy or Sell?
Based on moving averages and other technical indicators, the daily buy/sell signal is Neutral.
How Many Times Has ResMed Stock Split?
ResMed has split 4 times.
How Many Employees Does ResMed Have?
ResMed has 11370 employees.
What is the current trading status of ResMed (RMD)?
As of 07/11/2026, ResMed (RMD) is trading at a price of 235.30 USD, with a previous close of 235.30 USD. The stock has fluctuated within a day range of 231.95 USD to 236.67 USD, while its 52-week range spans from 180.27 USD to 277.67 USD.
What Is ResMed (RMD) Price Target According to Analysts?
The average 12-month price target for ResMed is 264.33 USD, with a high estimate of 320 USD and a low estimate of 210 USD. 9 analysts recommend buying the stock, while 1 suggest selling, leading to an overall rating of Buy. The stock has an +12.34% Upside potential.
What Is the RMD Premarket Price?
RMD's last pre-market stock price is 233.70 USD. The pre-market share volume is 890.00, and the stock has decreased by -5.61, or -2.34%.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.